Abstract
The management of heparin-induced thrombocytopenia (HIT) in pregnancy represents a medical challenge. The advent of new antithrombotic agents that do not cross-react with platelet factor 4 and heparin antibodies represents an important progress, and they are of utmost interest in special situations such as early pregnancy, a situation where the teratogenicity of warfarin precludes its use.
Vol. 91 No. 8_Suppl (2006): August, 2006 : Case Reports
Published By
Ferrata Storti Foundation, Pavia, Italy
Statistics from Altmetric.com